Advances in
monoclonal antibody (mAb) production have superseded the abilities of
downstream processing systems. Current production systems generate much higher
concentrations that cannot be handled by traditional separation processes.
Whether it is ion-exchange columns or centrifugation systems, processing
solutions with higher biomass has become a real challenge for the industry. At
the same time, the growth in the biosimilar market is placing downward cost
pressures on these downstream processes.
What do you
think can be done to address this issue? Is enough progress being made with
salt-tolerant and mixed-mode ion-exchange media? Will introduction of
single-use systems be effective in reducing costs in general? What about the
use of flocculation and precipitation? Membrane technology?
Beyond
specific new technology solutions, what new strategies might be adopted to help
overcome the challenges faced by mAb producers?
Share your thoughts and ideas.
Editor
No comments:
Post a Comment